- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy
- Behavioral
- Lead sponsor
- University of Missouri, Kansas City
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Kansas City, Missouri • West Orange, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 172
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 588 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 47
- States / cities
- Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Observation of Ocrelizumab as Treatment in RRMS Patients
- Other
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Interventions
- Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Other · Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 624
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Sonelokimab, Placebo
- Drug
- Lead sponsor
- MoonLake Immunotherapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 28
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, DMARDs
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- Gantenerumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 5 more
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
- Interventions
- ETC-1002, Placebo
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- John F. Foley, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Thyroid Diseases, Chronic Periodontitis
- Interventions
- NO intervention, patient records review only
- Other
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 4,965 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
- Interventions
- Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Rheumatoid Arthritis
- Interventions
- Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Rheumatoid Arthritis
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Early Undifferentiated Arthritis
- Interventions
- Not listed
- Lead sponsor
- California Pacific Medical Center Research Institute
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs, Oral corticosteroids
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 138
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 119 more
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
- Interventions
- Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol, Placebo, Methotrexate
- Biological · Other
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Ofatumumab, Disease modifying treatment (DMT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more
- Conditions
- Parkinson's Disease
- Interventions
- nicotine transdermal patch
- Drug
- Lead sponsor
- James BOYD MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sunnyvale, California • Honolulu, Hawaii + 6 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
- Conditions
- Fatigue, Multiple Sclerosis
- Interventions
- Ozanimod
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Fingolimod
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 694 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey